BLUEPRINT MED.CORP.DL-001BLUEPRINT MED.CORP.DL-001BLUEPRINT MED.CORP.DL-001

BLUEPRINT MED.CORP.DL-001

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪6.15 B‬EUR
−4.42EUR
‪−459.33 M‬EUR
‪225.94 M‬EUR
‪61.31 M‬
Beta (1Y)
1.05

About Blueprint Medicines Corporation

CEO
Kathryn Haviland
Headquarters
Cambridge
Employees (FY)
655
Founded
2008
FIGI
BBG008ML55Q6
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange BLUEPRINT MED.CORP.DL-001 stocks are traded under the ticker 2L9.
We've gathered analysts' opinions on BLUEPRINT MED.CORP.DL-001 future price: according to them, 2L9 price has a max estimate of 156.00 EUR and a min estimate of 69.64 EUR. Watch 2L9 chart and read a more detailed BLUEPRINT MED.CORP.DL-001 stock forecast: see what analysts think of BLUEPRINT MED.CORP.DL-001 and suggest that you do with its stocks.
2L9 reached its all-time high on Dec 21, 2020 with the price of 103.26 EUR, and its all-time low was 11.62 EUR and was reached on Feb 11, 2016. View more price dynamics on 2L9 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track BLUEPRINT MED.CORP.DL-001 financials in yearly and quarterly reports right on TradingView.
BLUEPRINT MED.CORP.DL-001 is going to release the next earnings report on Jul 31, 2024. Keep track of upcoming events with our Earnings Calendar.
2L9 earnings for the last quarter are 1.34 EUR per share, whereas the estimation was −1.54 EUR resulting in a 187.01% surprise. The estimated earnings for the next quarter are −1.19 EUR per share. See more details about BLUEPRINT MED.CORP.DL-001 earnings.
BLUEPRINT MED.CORP.DL-001 revenue for the last quarter amounts to ‪89.08 M‬ EUR despite the estimated figure of ‪74.97 M‬ EUR. In the next quarter revenue is expected to reach ‪94.78 M‬ EUR.
2L9 net income for the last quarter is ‪82.61 M‬ EUR, while the quarter before that showed ‪−100.49 M‬ EUR of net income which accounts for 182.20% change. Track more BLUEPRINT MED.CORP.DL-001 financial stats to get the full picture.
No, 2L9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 1, 2024, the company has 655.00 employees. See our rating of the largest employees — is BLUEPRINT MED.CORP.DL-001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BLUEPRINT MED.CORP.DL-001 EBITDA is ‪−392.54 M‬ EUR, and current EBITDA margin is −190.32%. See more stats in BLUEPRINT MED.CORP.DL-001 financial statements.
Like other stocks, 2L9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BLUEPRINT MED.CORP.DL-001 stock right from TradingView charts — choose your broker and connect to your account.